R&D News | pharmaphorum

News

Anavex hit as Rett syndrome drug flunks test

2024 has started on a low for US biotech Anavex Life Sciences, which saw its shares fall sharply this morning after Rett syndrome candidate Anavex 2-73 failed a clinical trial.

News

Novartis opens new frontier in Voyager gene therapy alliance

Novartis has doubled down on its gene therapy collaboration with Voyager Therapeutics, stumping up another $1.2 billion-plus in potential milestone payments and directing

News

Novo Nordisk will open AI hub in London

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug disco

News

Astellas strikes $1.7bn SIRP drug deal with Elpiscience

Astellas has struck a deal with fellow Japanese pharma company Elpiscience to develop up to four cancer immunotherapies that work by revving up the activity of macrophages

News

Cytokinetics rockets on positive heart drug trial

Shares in US biotech Cytokinetics have popped after a report that its aficamten drug improved symptoms in people with a rare and progressive form of heart disease.

News

BMS strikes again, with $4.1bn RayzeBio takeover bid

Bristol-Myers Squibb is having a busy holiday period, signing a $4.1 billion deal to acquire cancer drug developer RayzeBio – its second multibillion-dollar M&A deal i

Anavex hit as Rett syndrome drug flunks test

Novartis opens new frontier in Voyager gene therapy alliance

Novo Nordisk will open AI hub in London

Astellas strikes $1.7bn SIRP drug deal with Elpiscience

Cytokinetics rockets on positive heart drug trial

BMS strikes again, with $4.1bn RayzeBio takeover bid

FDA grants three priority vouchers to psychedelics

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks